Hostname: page-component-76fb5796d-45l2p Total loading time: 0 Render date: 2024-04-27T04:59:54.688Z Has data issue: false hasContentIssue false
  • English
  • Français

New classes of antidepressant drugs

Published online by Cambridge University Press:  02 January 2018

Allan I. F. Scott
Rights & Permissions [Opens in a new window]

Extract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

The January 1997 issue of this journal contained four reviews that compared tricyclic antidepressants with selective serotonin reuptake inhibitors (SSRIs) and other newer antidepressants in terms of their pharmacology (Palazidou, 1997), adverse effects, potential drug interactions and toxicity (Henry, 1997), efficacy in the prevention of relapse and recurrence (Edwards, 1997), and findings from meta-analyses (Anderson, 1997). In July 1997 reboxetine was promoted as the first selective noradrenaline reuptake inhibitor (NARI), and in October of the same year mirtazapine was promoted as the first noradrenergic and specific serotonergic antidepressant (NaSSA). Milnacipran is presently being registered by the manufacturers, after which it will be the second antidepressant drug promoted as a specific serotonin and noradrenaline reuptake inhibitor (SNRI).

Type
Research Article
Information
Advances in Psychiatric Treatment , Volume 5 , Issue 2 , March 1999 , pp. 104 - 111
Copyright
Copyright © The Royal College of Psychiatrists 1999 

References

Anderson, I. (1997) Lessons to be learnt from meta-analyses of newer versus older antidepressants. Advances in Psychiatric Treatment, 3, 58–63.CrossRefGoogle Scholar
Benkert, O., Grunder, G., Wetzel, H. et al (1996) Randomised, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia. Journal of Psychiatric Research, 30, 441–451.CrossRefGoogle ScholarPubMed
Berzewski, H., Van Moffaert, M. & Gagiano, C.A. (1997) Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive episodes. European Neuro-Psychopharmacology, 7 (suppl. 1), S37–S47.Google Scholar
de Boer, T. (1996) The pharmacologic profile of mirtazapine. Journal of Clinical Psychiatry, 57 (suppl. 4), 19–25.Google Scholar
Briley, M. (1998) Specific serotonin and noradrenaline reuptake inhibitors (SNRIs). A review of their pharmacology, clinical efficacy and tolerability. Human Psychopharmacology, 13, 99–111.3.0.CO;2-2>CrossRefGoogle Scholar
Burnett, F. E. & Dinan, T. G. (1998) Venlafaxine. Pharmacology and therapeutic potential in the treatment of depression. Human Psychopharmacology, 13, 153–162.Google Scholar
Clerc, G. E., Ruimy, P., Verdeau-Pailles, J. et al (1994) A double-blind comparison of venlafaxine and fluoxetine in patients hospitalised for major depression and melancholia. International Clinical Psychopharmacology, 9, 139–143.CrossRefGoogle ScholarPubMed
Dierick, M., Ravizza, L., Realini, R. et al (1996) A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 20, 57–71.Google Scholar
Dubini, A., Bosc, M. & Polin, V. (1997) Noradrenalineselective versus serotonin-selective antidepressant therapy: differential effects on social functioning. Journal of Psychopharmacology, 11 (suppl. 4), S17–S23.Google ScholarPubMed
Edwards, J. G. (1997) Prevention of relapse and recurrence of depression: newer versus older antidepressants. Advances in Psychiatric Treatment, 3, 52–57.CrossRefGoogle Scholar
Frazer, A. (1997) Pharmacology of antidepressants. Journal of Clinical Psychopharmacology, 17 (suppl. 1), 2S–18S Google Scholar
Guelfi, J. D., White, C., Hackett, D. et al (1995) Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. Journal of Clinical Psychiatry, 56, 450–458.Google Scholar
Henry, J. A. (1997) Toxicity of newer versus older antidepressants. Advances in Psychiatric Treatment, 3, 41–45.CrossRefGoogle Scholar
Kasper, S. (1995) Clinical efficacy of mirtazapine: a review of meta-analyses of pooled data. International Clinical Psychopharmacology, 10 (suppl. 4), 25–37.Google Scholar
Montgomery, S. A. (1997) Reboxetine: additional benefits to the depressed patient. Journal of Psychopharmacology, 11, (suppl. 4), S9–S15.Google Scholar
Mucci, M. (1997) Reboxetine: a review of antidepressant tolerability. Journal of Psychopharmacology, 11 (suppl. 4) S33–S37.Google Scholar
Palazidou, E. (1997) Development of new antidepressants. Advances in Psychiatric Treatment, 3, 46–51.Google Scholar
Puech, A., Montgomery, S. A., Prost, J. F. et al (1997) Milnacipran, a new serotonin and noradrenaline re-uptake inhibitor; an overview of its antidepressant activity and clinical tolerability. International Clinical Psychopharmacology, 12, 99–108.CrossRefGoogle Scholar
Redmond, A. M. & Leonard, B. E. (1997) An evaluation of the role of the noradrenergic system in the neurobiology of depression: review. Human Psychopharmacology, 12, 407–430.3.0.CO;2-1>CrossRefGoogle Scholar
Richou, H., Ruimy, P., Charbaut, J. et al (1995) A multi-centre, double-blind, clomipramine-controlled efficacy and safety study of org 3770. Human Psychopharmcology, 10, 263–271.CrossRefGoogle Scholar
Robertson, M. M., Abou-Saleh, M. T., Harrison, D. A. et al (1994) A double-blind controlled comparison of fluoxetine and lofepramine in major depressive illness. Journal of Psychopharmacology, 8, 98–103.Google Scholar
Rudolph, R. L., Fabre, L. F., Feighner, J. P. et al (1998) A randomised, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. Journal of Clinical Psychiatry, 59, 116–122.CrossRefGoogle ScholarPubMed
Samuelian, J. C., Tatossina, A. & Hackett, D. (1992) A randomised double-blind, parallel group comparison of venlafaxine and clomipramine in outpatients with major depression. Clinical Neuropharmacology, 15 (suppl. 1), 324B.Google Scholar
Tylee, A., Beaumont, G., Bowden, M. W. et al (1997) A double-blind, randomised, 12-week comparison study the safety and efficacy of venlafaxine and fluoxetine in moderate to severe major depression in general practice. Primary Care Psychiatry, 3, 51–58.Google Scholar
Wheatley, D. P., Van Moffaert, M., Timmerman, L. et al (1998) Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Journal of Clinical Psychiatry, 59, 306–312.Google Scholar
Zivkov, M. & de Jongh, G. (1995) Org 3770 versus amitriptyline: a six-week randomised double-blind multicentred trial in hospitalised patients. Human Psychopharmacology, 10, 173–180.CrossRefGoogle Scholar
Zivkov, M., Roes, K. C. B. & Pols, A. G. (1995) Efficacy of org 3770 (mirtazapine) versus amitriptyline in patients with major depressive disorder: a meta-analysis. Human Psychopharmacology, 10 (suppl. 2), S135–S145.CrossRefGoogle Scholar
Submit a response

eLetters

No eLetters have been published for this article.